Therapeutics Inc.

Pharmacy Choice | January 18, 2017

By a News Reporter-Staff News Editor at Biotech Week APT Therapeutics, Inc., a privately-held biopharmaceutical company, announced a research collaboration, option and asset purchase agreement with AstraZeneca. APT Therapeutics has applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Uniquely different than current FDA-approved antithrombotic drugs that can increase bleeding risk, APT102 attenuated clo...

Precision Therapeutics Inc. | April 11, 2019

PITTSBURGH, April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available...

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...